| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,200,000 |
| Market
Cap: |
110.15(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.5 - $7.84 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 10.2 |
| Insider 6 Months : 10.2 |
| Insider 3/6 Months : 20.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
200,000 |
200,000 |
1,104,977 |
1,121,909 |
| Total Buy Value |
$321,920 |
$321,920 |
$4,321,918 |
$4,427,874 |
| Total People Bought |
2 |
2 |
3 |
4 |
| Total Buy Transactions |
5 |
5 |
6 |
8 |
| Total Shares Sold |
34,837 |
45,438 |
58,012 |
66,049 |
| Total Sell Value |
$178,365 |
$230,844 |
$286,799 |
$318,236 |
| Total People Sold |
1 |
2 |
2 |
3 |
| Total Sell Transactions |
1 |
3 |
5 |
7 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nelsen Robert |
10% Owner |
– – • |
2019-03-12 |
4 |
S |
$7.37 |
$295,374 |
D/D |
(40,092) |
4,432,462 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2019-03-11 |
4 |
S |
$6.49 |
$291,366 |
D/D |
(44,878) |
4,472,554 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2019-03-08 |
4 |
S |
$6.93 |
$585,270 |
D/D |
(84,496) |
4,517,432 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2019-03-07 |
4 |
S |
$6.87 |
$242,013 |
D/D |
(35,209) |
4,601,928 |
|
- |
|
| Simonian Nancy A |
President & CEO |
• • – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
188,000 |
669,288 |
|
- |
|
| Ferra Joseph J Jr |
Chief Financial Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
87,000 |
|
- |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
87,000 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
87,000 |
|
- |
|
| Quirk Gerald E |
Chief Legal & Admin. Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
87,000 |
|
- |
|
| Springhorn Jeremy P. |
Chief Business Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
102,000 |
|
- |
|
| Simonian Nancy A |
President & CEO |
• • – |
2018-11-29 |
4 |
OE |
$1.01 |
$136,224 |
D/D |
110,588 |
481,288 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2018-01-31 |
4 |
B |
$9.55 |
$1,999,999 |
I/I |
209,424 |
1,059,938 |
2.1 |
- |
|
| Springhorn Jeremy P. |
Chief Business Officer |
• – – |
2017-12-15 |
4 |
B |
$9.08 |
$136,260 |
D/D |
15,000 |
15,000 |
2.74 |
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2017-12-14 |
4 |
B |
$8.99 |
$239,134 |
I/I |
26,600 |
830,494 |
2.1 |
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2017-12-13 |
4 |
B |
$8.97 |
$613,548 |
I/I |
68,400 |
803,894 |
2.1 |
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2017-12-12 |
4 |
B |
$9.40 |
$138,876 |
I/I |
14,774 |
735,494 |
2.1 |
- |
|
| Desimone Colleen Elizabeth |
Principal Accounting Officer |
• – – |
2017-10-23 |
4 |
AS |
$16.06 |
$8,833 |
D/D |
(550) |
0 |
|
- |
|
| Desimone Colleen Elizabeth |
Principal Accounting Officer |
• – – |
2017-10-23 |
4 |
OE |
$3.04 |
$1,672 |
D/D |
550 |
550 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2017-08-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(360,515) |
0 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2017-08-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,295,997) |
2,378,663 |
|
- |
|
| Young Richard A |
Director |
– • – |
2017-08-14 |
4 |
AS |
$22.00 |
$72,204 |
D/D |
(3,282) |
420,101 |
|
- |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2017-07-25 |
4 |
AS |
$21.85 |
$273,125 |
D/D |
(12,500) |
0 |
|
- |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2017-07-25 |
4 |
OE |
$1.01 |
$12,625 |
D/D |
12,500 |
12,500 |
|
- |
|
| Young Richard A |
Director |
– • – |
2017-07-25 |
4 |
AS |
$22.09 |
$72,496 |
D/D |
(3,282) |
423,383 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2017-06-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
720,720 |
|
- |
|
157 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (2.08%) 
